# Filippo de Marinis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/filippo-de-marinis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 47,491 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 81 |
| i10-index | 320 |
| OpenAlex ID | https://openalex.org/A5003664573 |
| ORCID iD | https://orcid.org/0000-0002-1118-5536 |
| Works | 725 |

## Researcher papers

Showing 12 of 18.

- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-comparing-cisplatin-plus-gemcitabine-with-cisplatin-plus/)
- [Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy](https://scholariq.org/papers/randomized-phase-iii-trial-of-pemetrexed-versus-docetaxel-in-patients-with-non/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial](https://scholariq.org/papers/cetuximab-plus-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer/)
- [First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/first-line-lorlatinib-or-crizotinib-in-advanced-i-alk-i-positive-lung-cancer/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-resected-i-egfr-i-mutated-nsclc/)
- [Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/amivantamab-plus-lazertinib-in-previously-untreated-i-egfr-i-mutated-advanced/)
- [Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial](https://scholariq.org/papers/adjuvant-osimertinib-for-resected-egfr-mutated-stage-ib-iiia-non-small-cell-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.